Thrombotic Thrombocytopenic Purpura A diagnostic Emergency.

Jennifer Mills

Clinical Scientist: Haematology and Transfusion.



Session Aims



TTP 101

Overview of the disorder and its classifications.



Diagnosing TTP

Full blood count, peripheral blood and differential diagnosis features.



Managing TTP

How TTP is managed, and the laboraty's role.



Things to consider to avoid missing a diagnosis.

TTP 101

Rare

Currently 6 six cases per million per year, the majority of which are female.

1° TTP

Presents in childhood. Results from a congenital lack of ADAMTS13

Difficult to Diagnose

There is much morphological and clinical crossover with other disorders, making it difficult to diagnose.

2° TTP

Presents in adulthood. Results from autoimmune response which removes ADAMTS13 from circulation

TTP 101

Thrombotic Thrombocytopenic Purpura



- Without ADAMTS13, vWF remains incredibly "sticky"
- It activates platelets, even without vascular damage.
- This produces small, unfixed clots which lodge in vessels.
- The resulting thrombocytopenia causes bleeding.



FBC at Presentation

11/11/	27/11/	10/02/2023 13:40 Blood					
Reque	Reque	Request Reason : IUT Jerse	y, HELL	P syndrome,	pregnant for	' urgent de	elivery.
ЦВ		NO					
WRC	HB						
PLT	WBC	HB	91	g/L	(120	to 150) Auth
RBC	PLT	WBC	13.9	10 * 9/L	(4.0	to 11.0) Auth
HCT	RBC	PLT	24	10 * 9/L	(156	to 410) Auth
MCU	HCT	RBC	2.90	10 * 12/L	(3.80	to 4.80) Auth
MCHC	MCV	HCT	0.262	L/L	(0.360	to 0.460) Auth
RDW	MCH	MCV	90.1	fL	(83	to 101) Auth
MPV	MCHC	MCH	31.3	pg	(27.0	to 32.0) Auth
Neutr	RDW	MCHC	348	g/L	(315	i to 345) Auth
Lymph	MPV	RDW	16.6		(11.6	to 14.0) Auth
MUNUC	Neutr	MPV	6.6	fL	(7.5	to 11.2) Auth
Eosin	Lympr	Neutrophils	12.2	10 * 9/L	(2.0	to 7.0) Auth
BHS Neutr	Monoc	Lymphocytes	1.2	10 × 9/L	(1.0	to 3.0) Auth
Monoc	Eosir	Monocytes	0.4	10 * 9/L	(0.2	to 1.0) Auth
Autom	BAS	Eosinophils	0.0	10 * 9/L	(0.00	to 0.5) Auth
uncor	Autor	BAS	0.0	10 * 9/L	(0.0	to 0.1) Auth
Detic	uncor	Neutrophil-Lymphocyte Ratio	10.2	Ratio			Auth
Immat	Retic	Automated Nucleated Red Count	^0.1	10 * 9/L	(0.0	to 0.1) Auth
Retic	Immat	uncorrected WBC	^13.9	10 * 9/L			Auth



Differential Diagnosis

Haemolytic Uraemic Syndrome

- Fragments
- Thrombocytopenia
- Normal clotting

Promyelocytic Leukaemia

- Fragments
- Thrombocytopenia
- Deranged clotting

Disseminated Intravascular Haemolysis

- Fragments
- Thrombocytopenia
- Deranged clotting

Severe Megaloblastosis

- Fragments
- Thrombocytopenia
- Normal clotting

HELLP Syndrome

- Fragments
- Thrombocytopenia
- Normal clotting

Autoimmune Haemolysis

- Fragments
- Normal platelets
- Normal clotting

	Confirmatory Tests								
	Test	Finding in TTP	Use in differential diagnosis						
	Clotting (INR/APTR/FIB)	Normal	Rules out DIC						
	Lactate Dehydrogenase	$\uparrow\uparrow\uparrow$	Proves increased cell turnover						
_	Direct Antiglobulin Test	Negative	Rules out AIHA						
_	Haptoglobin	$\downarrow\downarrow\downarrow\downarrow$	Proves intravascular haemolysis						
	Reticulocytes	$\uparrow \uparrow \uparrow$	Confirms marrow compensation						
	B12/Folate	Normal	Rules out megaloblastosis						

ADAMTS13 Testing



ADAMTS13 Activity of **<10IU/L** is diagnostic for TTP and rules out other disorders e.g. HUS.

Antibodies are found in secondary (aquired) TTP, but not in congenital TTP.

Reference labs typically use ELISAs. There are new, validated methods available for activity, but can underestimate levels.

Management of TTP

Congenital

- These patients need ADAMTS13 replacement.
- This may be FFP or recombinant ADAMTS13.
- They DO NOT need plasma exchange.

Secondary

- Plasma exchange with a standardised plasma product.
- This continues until the platelets normalise.
- Additionally steroids are given.
- Red cells should be given to resolve anaemia.
- Platelets should ONLY be given in severe bleeding.

Why do we Worry?



%

TTP is FATAL!

Without prompt treatment, patients can suffer severe morbidity and mortality.

TTP is fatal in 50% of cases, if the patient is not treated within 24hours of presentation.



TTP is TREATABLE!

>90% of patients will make a full recovery from TTP if treated promptly.

The faster treatment started, the lower the risk of severe comorbidities.

TTP Considerations



Thanks!

Do you have any questions?

Jennifer.mills@porthosp.nhs.uk 023 92 28 5774

Please keep this slide for attribution

CREDITS: This presentation template was created by **Slidesgo**, including icons by **Flaticon**, infographics & images by **Freepik**

